Sutro Biopharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Sutro Biopharma, Inc. on April 14, 2023, covering events occurring on April 10, 2023. The report addresses corporate governance changes regarding the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Director Resignation: Shalini Sharp resigned as a Class III director and Chair of the Audit Committee, effective immediately on April 10, 2023.
- Reason for Departure: The resignation did not result from any disagreements with the Company's management or the Board.
- Appointment: The Board appointed Heidi Hunter, a Class I director and existing Audit Committee member, as the new Chair of the Audit Committee, effective April 13, 2023.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on operations, or discussion of risks and contingencies beyond the standard disclosure regarding the director's departure.
Key Facts for Investor Verification
- Confirm the effective date of Heidi Hunter's appointment as Audit Committee Chair (April 13, 2023).
- Verify the composition of the Audit Committee following the resignation of Shalini Sharp.
- Review subsequent filings to determine if a new Class III director was nominated to fill the vacancy.